Trial Outcomes & Findings for Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease (NCT NCT00296400)

NCT ID: NCT00296400

Last Updated: 2011-06-16

Results Overview

Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine protein/creatinine ratio over baseline urine protein/creatinine ratio.

• Recruitment status: COMPLETED
• Study phase: PHASE2
• Target enrollment: 237 participants
• Primary outcome timeframe: Assessed at baseline and Week 52 (LOCF)
• Results posted on: 2011-06-16

Participant Flow

797 patients entered the study with moderate proteinuria and hypercholesterolemia and were receiving stable treatment with angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs) for 3 or more months prior to Visit 1. The study was conducted at 114 participating centers in 11 countries.

237 patients [pts] completed the 8-week lead-in period and were randomized. The most common reasons for discontinuation during the lead in period included incorrect enrollment (466 pts), development of study-specific discontinuation criteria (41 pts), and voluntary discontinuation (29 pts). 189 patients completed the study.

Participant milestones

Measure	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
Overall Study COMPLETED	53	69	67
Overall Study NOT COMPLETED	17	18	13
Overall Study STARTED	70	87	80

Reasons for withdrawal

Measure	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
Overall Study Adverse Event	7	7	7
Overall Study Withdrawal by Subject	5	6	2
Overall Study Incorrect enrollment	2	0	0
Overall Study Protocol Violation	1	1	1
Overall Study Lost to Follow-up	1	1	2
Overall Study Study specific discontinuation criteria	0	0	1
Overall Study Visit 10 was performed earlier	0	1	0
Overall Study Pregnancy	1	2	0

Baseline Characteristics

Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease

Baseline characteristics by cohort

Measure	Rosuvastatin 10 mg n=70 Participants	Rosuvastatin 40 mg n=87 Participants	Atorvastatin 80 mg n=80 Participants	Total n=237 Participants Total of all reporting groups
Age, Customized 18 to 49 years	34 Participants n=5 Participants	44 Participants n=7 Participants	42 Participants n=5 Participants	120 Participants n=4 Participants
Age, Customized 50 to 64 years	31 Participants n=5 Participants	31 Participants n=7 Participants	30 Participants n=5 Participants	92 Participants n=4 Participants
Age, Customized >=65 years	5 Participants n=5 Participants	12 Participants n=7 Participants	8 Participants n=5 Participants	25 Participants n=4 Participants
Sex: Female, Male Female	28 Participants n=5 Participants	35 Participants n=7 Participants	31 Participants n=5 Participants	94 Participants n=4 Participants
Sex: Female, Male Male	42 Participants n=5 Participants	52 Participants n=7 Participants	49 Participants n=5 Participants	143 Participants n=4 Participants
Estimated glomerular filtration rate [eGFR]	78.315 mL/min STANDARD_DEVIATION 28.0653 • n=5 Participants	76.774 mL/min STANDARD_DEVIATION 30.3878 • n=7 Participants	71.464 mL/min STANDARD_DEVIATION 30.0156 • n=5 Participants	75.419 mL/min STANDARD_DEVIATION 29.6012 • n=4 Participants
Urine albumin/creatinine ratio	1023.165 mg/g STANDARD_DEVIATION 720.0251 • n=5 Participants	1167.368 mg/g STANDARD_DEVIATION 865.4584 • n=7 Participants	1069.103 mg/g STANDARD_DEVIATION 720.8011 • n=5 Participants	1091.263 mg/g STANDARD_DEVIATION 775.1889 • n=4 Participants
Urine protein/creatinine ratio	1301.163 mg/g STANDARD_DEVIATION 832.7398 • n=5 Participants	1487.131 mg/g STANDARD_DEVIATION 1068.0642 • n=7 Participants	1439.720 mg/g STANDARD_DEVIATION 991.2295 • n=5 Participants	1416.023 mg/g STANDARD_DEVIATION 975.7636 • n=4 Participants

PRIMARY outcome

Timeframe: Assessed at baseline and Week 52 (LOCF)

Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 [LOCF] urine protein/creatinine ratio over baseline urine protein/creatinine ratio.

Outcome measures

Measure	Rosuvastatin 10 mg n=65 Participants	Rosuvastatin 40 mg n=80 Participants	Atorvastatin 80 mg n=75 Participants
Urinary Protein/Creatinine Ratio at Week 52 [LOCF]	0.938 ratio Interval 0.725 to 1.212	1.082 ratio Interval 0.927 to 1.262	0.759 ratio Interval 0.636 to 0.905

SECONDARY outcome

Timeframe: Assessed at baseline and Week 26

Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine protein/creatinine ratio over baseline urine protein/creatinine ratio.

Outcome measures

Measure	Rosuvastatin 10 mg n=59 Participants	Rosuvastatin 40 mg n=76 Participants	Atorvastatin 80 mg n=70 Participants
Urinary Protein/Creatinine Ratio at Week 26.	0.932 ratio Interval 0.721 to 1.203	1.057 ratio Interval 0.898 to 1.244	0.762 ratio Interval 0.631 to 0.921

SECONDARY outcome

Timeframe: Assessed at baseline and Week 26

Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.

Outcome measures

Measure	Rosuvastatin 10 mg n=60 Participants	Rosuvastatin 40 mg n=76 Participants	Atorvastatin 80 mg n=72 Participants
Urinary Albumin/Creatinine Ratio at Week 26	0.850 ratio Interval 0.631 to 1.143	0.946 ratio Interval 0.789 to 1.135	0.731 ratio Interval 0.601 to 0.889

SECONDARY outcome

Timeframe: Assessed at baseline and Week 52 [LOCF]

Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 [LOCF] urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.

Outcome measures

Measure	Rosuvastatin 10 mg n=65 Participants	Rosuvastatin 40 mg n=80 Participants	Atorvastatin 80 mg n=75 Participants
Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]	0.879 ratio Interval 0.652 to 1.185	0.967 ratio Interval 0.814 to 1.148	0.719 ratio Interval 0.587 to 0.882

SECONDARY outcome

Timeframe: Assessed at baseline and Week 26

The change from baseline in eGFR at Week 26 is the Week 26 value minus baseline value.

Outcome measures

Measure	Rosuvastatin 10 mg n=60 Participants	Rosuvastatin 40 mg n=77 Participants	Atorvastatin 80 mg n=72 Participants
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26	1.39 mL/min Standard Deviation 15.431 • Interval 15.431 to	-3.41 mL/min Standard Deviation 13.228 • Interval 13.228 to	-1.61 mL/min Standard Deviation 9.494 • Interval 9.494 to

SECONDARY outcome

Timeframe: Assessed at baseline and Week 52 [LOCF]

The change from baseline in eGFR at Week 52 [LOCF] is the Week 52 value or last observation carried forward minus baseline value.

Outcome measures

Measure	Rosuvastatin 10 mg n=65 Participants	Rosuvastatin 40 mg n=80 Participants	Atorvastatin 80 mg n=75 Participants
Change From Baseline in eGFR at Week 52 [LOCF]	-2.71 mL/min Standard Deviation 13.083 • Interval 13.083 to	-3.30 mL/min Standard Deviation 12.325 • Interval 12.325 to	-1.74 mL/min Standard Deviation 13.964 • Interval 13.964 to

SECONDARY outcome

Timeframe: baseline and 26 weeks

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=135 Participants	Rosuvastatin 40 mg n=70 Participants	Atorvastatin 80 mg n=205 Participants
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 26.	0.17601 Correlation coefficient	0.21701 Correlation coefficient	0.19643 Correlation coefficient

SECONDARY outcome

Timeframe: 52 weeks

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=121 Participants	Rosuvastatin 40 mg n=64 Participants	Atorvastatin 80 mg n=185 Participants
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 52.	0.20462 Correlation coefficient	0.03480 Correlation coefficient	0.16077 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=135 Participants	Rosuvastatin 40 mg n=69 Participants	Atorvastatin 80 mg n=204 Participants
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 26	0.14302 Correlation coefficient	0.24393 Correlation coefficient	0.17632 Correlation coefficient

SECONDARY outcome

Timeframe: 52 weeks

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=121 Participants	Rosuvastatin 40 mg n=62 Participants	Atorvastatin 80 mg n=183 Participants
Correlation of Changes From Baseline inUrinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C	0.16868 Correlation coefficient	-0.09428 Correlation coefficient	0.10679 Correlation coefficient

SECONDARY outcome

Timeframe: 26 weeks

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=135 Participants	Rosuvastatin 40 mg n=69 Participants	Atorvastatin 80 mg n=204 Participants
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in High Density Lipoprotein Cholesterol [HDL-C] at Week 26	0.18055 Correlation coefficient	0.24987 Correlation coefficient	0.22094 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=121 Participants	Rosuvastatin 40 mg n=62 Participants	Atorvastatin 80 mg n=183 Participants
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52	0.20346 Correlation coefficient	0.18041 Correlation coefficient	0.20818 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.

)

Outcome measures

Measure	Rosuvastatin 10 mg n=135 Participants	Rosuvastatin 40 mg n=69 Participants	Atorvastatin 80 mg n=204 Participants
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol [nonHDL-C] at Week 26	0.16206 Correlation coefficient	0.20032 Correlation coefficient	0.17628 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=121 Participants	Rosuvastatin 40 mg n=62 Participants	Atorvastatin 80 mg n=183 Participants
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52	0.20386 Correlation coefficient	-0.04698 Correlation coefficient	0.14495 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=135 Participants	Rosuvastatin 40 mg n=70 Participants	Atorvastatin 80 mg n=205 Participants
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Triglyceride [TG] at Week 26	0.15348 Correlation coefficient	-0.06049 Correlation coefficient	0.10089 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=121 Participants	Rosuvastatin 40 mg n=64 Participants	Atorvastatin 80 mg n=185 Participants
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TG at Week 52	0.20659 Correlation coefficient	0.23989 Correlation coefficient	0.21728 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=135 Participants	Rosuvastatin 40 mg n=69 Participants	Atorvastatin 80 mg n=204 Participants
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26	0.04652 Correlation coefficient	0.06344 Correlation coefficient	0.04149 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=121 Participants	Rosuvastatin 40 mg n=62 Participants	Atorvastatin 80 mg n=183 Participants
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52	0.03957 Correlation coefficient	-0.17644 Correlation coefficient	-0.01549 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=135 Participants	Rosuvastatin 40 mg n=69 Participants	Atorvastatin 80 mg n=204 Participants
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26	0.06383 Correlation coefficient	0.12687 Correlation coefficient	0.07462 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=121 Participants	Rosuvastatin 40 mg n=62 Participants	Atorvastatin 80 mg n=183 Participants
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52	0.05881 Correlation coefficient	-0.20262 Correlation coefficient	-0.01340 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=135 Participants	Rosuvastatin 40 mg n=69 Participants	Atorvastatin 80 mg n=204 Participants
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26	0.06794 Correlation coefficient	0.05410 Correlation coefficient	0.05465 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=121 Participants	Rosuvastatin 40 mg n=62 Participants	Atorvastatin 80 mg n=183 Participants
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52	0.07188 Correlation coefficient	-0.16669 Correlation coefficient	0.00955 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=131 Participants	Rosuvastatin 40 mg n=67 Participants	Atorvastatin 80 mg n=198 Participants
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein A-1 [ApoA-1] at Week 26	0.12595 Correlation coefficient	0.05628 Correlation coefficient	0.13754 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=116 Participants	Rosuvastatin 40 mg n=62 Participants	Atorvastatin 80 mg n=178 Participants
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52	0.19626 Correlation coefficient	0.09835 Correlation coefficient	0.18349 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=131 Participants	Rosuvastatin 40 mg n=67 Participants	Atorvastatin 80 mg n=198 Participants
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein B [ApoB] at Week 26	0.18504 Correlation coefficient	0.17259 Correlation coefficient	0.19146 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=116 Participants	Rosuvastatin 40 mg n=62 Participants	Atorvastatin 80 mg n=178 Participants
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52	0.18473 Correlation coefficient	-0.02690 Correlation coefficient	0.12496 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=131 Participants	Rosuvastatin 40 mg n=67 Participants	Atorvastatin 80 mg n=198 Participants
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26	0.10698 Correlation coefficient	0.13814 Correlation coefficient	0.11414 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=116 Participants	Rosuvastatin 40 mg n=62 Participants	Atorvastatin 80 mg n=178 Participants
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52	0.05859 Correlation coefficient	-0.12938 Correlation coefficient	-0.00540 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=136 Participants	Rosuvastatin 40 mg n=72 Participants	Atorvastatin 80 mg n=208 Participants
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 26	0.18188 Correlation coefficient	0.17503 Correlation coefficient	0.18566 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=121 Participants	Rosuvastatin 40 mg n=65 Participants	Atorvastatin 80 mg n=186 Participants
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 52	0.23734 Correlation coefficient	0.01311 Correlation coefficient	0.17958 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=136 Participants	Rosuvastatin 40 mg n=71 Participants	Atorvastatin 80 mg n=207 Participants
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 26	0.14783 Correlation coefficient	0.21561 Correlation coefficient	0.16899 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=121 Participants	Rosuvastatin 40 mg n=63 Participants	Atorvastatin 80 mg n=184 Participants
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 52	0.20285 Correlation coefficient	-0.13565 Correlation coefficient	0.12568 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=136 Participants	Rosuvastatin 40 mg n=71 Participants	Atorvastatin 80 mg n=207 Participants
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 26	0.23547 Correlation coefficient	0.25043 Correlation coefficient	0.25208 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=121 Participants	Rosuvastatin 40 mg n=63 Participants	Atorvastatin 80 mg n=184 Participants
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52	0.17479 Correlation coefficient	0.18677 Correlation coefficient	0.18203 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=136 Participants	Rosuvastatin 40 mg n=71 Participants	Atorvastatin 80 mg n=207 Participants
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 26	0.16080 Correlation coefficient	0.17150 Correlation coefficient	0.16578 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=121 Participants	Rosuvastatin 40 mg n=63 Participants	Atorvastatin 80 mg n=184 Participants
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52	0.24107 Correlation coefficient	-0.08640 Correlation coefficient	0.16525 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=136 Participants	Rosuvastatin 40 mg n=72 Participants	Atorvastatin 80 mg n=208 Participants
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 26	0.11526 Correlation coefficient	-0.06890 Correlation coefficient	0.07248 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=121 Participants	Rosuvastatin 40 mg n=65 Participants	Atorvastatin 80 mg n=186 Participants
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 52	0.21730 Correlation coefficient	0.21151 Correlation coefficient	0.21477 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=136 Participants	Rosuvastatin 40 mg n=71 Participants	Atorvastatin 80 mg n=207 Participants
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26	0.02506 Correlation coefficient	0.02201 Correlation coefficient	0.01860 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=121 Participants	Rosuvastatin 40 mg n=63 Participants	Atorvastatin 80 mg n=184 Participants
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52	0.08954 Correlation coefficient	-0.20870 Correlation coefficient	0.01926 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=136 Participants	Rosuvastatin 40 mg n=71 Participants	Atorvastatin 80 mg n=207 Participants
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26	0.05037 Correlation coefficient	0.09779 Correlation coefficient	0.05936 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=121 Participants	Rosuvastatin 40 mg n=63 Participants	Atorvastatin 80 mg n=184 Participants
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52	0.10365 Correlation coefficient	-0.24717 Correlation coefficient	0.01386 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=136 Participants	Rosuvastatin 40 mg n=71 Participants	Atorvastatin 80 mg n=207 Participants
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26	0.04955 Correlation coefficient	0.02740 Correlation coefficient	0.03798 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=121 Participants	Rosuvastatin 40 mg n=63 Participants	Atorvastatin 80 mg n=184 Participants
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52	0.11997 Correlation coefficient	-0.21073 Correlation coefficient	0.03955 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=131 Participants	Rosuvastatin 40 mg n=68 Participants	Atorvastatin 80 mg n=199 Participants
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 26	0.16499 Correlation coefficient	0.02609 Correlation coefficient	0.15049 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=116 Participants	Rosuvastatin 40 mg n=63 Participants	Atorvastatin 80 mg n=179 Participants
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52	0.20021 Correlation coefficient	0.12953 Correlation coefficient	0.18870 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=131 Participants	Rosuvastatin 40 mg n=68 Participants	Atorvastatin 80 mg n=199 Participants
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 26	0.18720 Correlation coefficient	0.16167 Correlation coefficient	0.18717 Correlation coefficient

SECONDARY outcome

Timeframe: 52 weeks

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=116 Participants	Rosuvastatin 40 mg n=63 Participants	Atorvastatin 80 mg n=179 Participants
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52	0.21082 Correlation coefficient	-0.04379 Correlation coefficient	0.14085 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=131 Participants	Rosuvastatin 40 mg n=68 Participants	Atorvastatin 80 mg n=199 Participants
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26	0.10258 Correlation coefficient	0.13505 Correlation coefficient	0.11103 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=116 Participants	Rosuvastatin 40 mg n=63 Participants	Atorvastatin 80 mg n=179 Participants
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52	0.08108 Correlation coefficient	-0.16753 Correlation coefficient	0.00479 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=137 Participants	Rosuvastatin 40 mg n=72 Participants	Atorvastatin 80 mg n=209 Participants
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 26	0.06641 Correlation coefficient	-0.07964 Correlation coefficient	0.02900 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=121 Participants	Rosuvastatin 40 mg n=65 Participants	Atorvastatin 80 mg n=186 Participants
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 52	-0.15721 Correlation coefficient	0.16110 Correlation coefficient	-0.05794 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=137 Participants	Rosuvastatin 40 mg n=71 Participants	Atorvastatin 80 mg n=208 Participants
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 26	0.02679 Correlation coefficient	-0.07603 Correlation coefficient	-0.00171 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=121 Participants	Rosuvastatin 40 mg n=63 Participants	Atorvastatin 80 mg n=184 Participants
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 52	-0.15731 Correlation coefficient	0.15368 Correlation coefficient	-0.06310 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=137 Participants	Rosuvastatin 40 mg n=71 Participants	Atorvastatin 80 mg n=208 Participants
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 26	0.01684 Correlation coefficient	0.01755 Correlation coefficient	0.01758 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=121 Participants	Rosuvastatin 40 mg n=63 Participants	Atorvastatin 80 mg n=184 Participants
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 52	0.14080 Correlation coefficient	0.02750 Correlation coefficient	0.09472 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=137 Participants	Rosuvastatin 40 mg n=71 Participants	Atorvastatin 80 mg n=208 Participants
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 26	0.06029 Correlation coefficient	-0.08151 Correlation coefficient	0.02283 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=121 Participants	Rosuvastatin 40 mg n=63 Participants	Atorvastatin 80 mg n=184 Participants
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 52	-0.19532 Correlation coefficient	0.14967 Correlation coefficient	-0.09001 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=137 Participants	Rosuvastatin 40 mg n=72 Participants	Atorvastatin 80 mg n=209 Participants
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG at Week 26	0.04160 Correlation coefficient	0.00531 Correlation coefficient	0.03430 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=121 Participants	Rosuvastatin 40 mg n=65 Participants	Atorvastatin 80 mg n=186 Participants
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG	-0.12643 Correlation coefficient	0.00486 Correlation coefficient	-0.08301 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=137 Participants	Rosuvastatin 40 mg n=71 Participants	Atorvastatin 80 mg n=208 Participants
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 26	0.08194 Correlation coefficient	-0.06576 Correlation coefficient	0.04477 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=121 Participants	Rosuvastatin 40 mg n=63 Participants	Atorvastatin 80 mg n=184 Participants
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 52	-0.23597 Correlation coefficient	0.19933 Correlation coefficient	-0.10205 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=137 Participants	Rosuvastatin 40 mg n=71 Participants	Atorvastatin 80 mg n=208 Participants
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26	0.04858 Correlation coefficient	-0.05535 Correlation coefficient	0.02023 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=121 Participants	Rosuvastatin 40 mg n=63 Participants	Atorvastatin 80 mg n=184 Participants
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52	-0.20805 Correlation coefficient	0.18299 Correlation coefficient	-0.07681 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=137 Participants	Rosuvastatin 40 mg n=71 Participants	Atorvastatin 80 mg n=208 Participants
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26	0.08263 Correlation coefficient	-0.06860 Correlation coefficient	0.04337 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=121 Participants	Rosuvastatin 40 mg n=63 Participants	Atorvastatin 80 mg n=184 Participants
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52	-0.23887 Correlation coefficient	0.17170 Correlation coefficient	-0.10817 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=132 Participants	Rosuvastatin 40 mg n=68 Participants	Atorvastatin 80 mg n=200 Participants
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 26	0.13029 Correlation coefficient	0.17554 Correlation coefficient	0.14191 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=116 Participants	Rosuvastatin 40 mg n=63 Participants	Atorvastatin 80 mg n=179 Participants
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 52	0.11047 Correlation coefficient	0.07751 Correlation coefficient	0.08580 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=132 Participants	Rosuvastatin 40 mg n=68 Participants	Atorvastatin 80 mg n=200 Participants
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 26	0.06098 Correlation coefficient	-0.03181 Correlation coefficient	0.03861 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=116 Participants	Rosuvastatin 40 mg n=63 Participants	Atorvastatin 80 mg n=179 Participants
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 52	-0.11217 Correlation coefficient	0.11006 Correlation coefficient	-0.03932 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 26 weeks

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=132 Participants	Rosuvastatin 40 mg n=68 Participants	Atorvastatin 80 mg n=200 Participants
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26	0.02907 Correlation coefficient	-0.09476 Correlation coefficient	-0.00160 Correlation coefficient

SECONDARY outcome

Timeframe: Baseline and 52 weeks

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Outcome measures

Measure	Rosuvastatin 10 mg n=116 Participants	Rosuvastatin 40 mg n=63 Participants	Atorvastatin 80 mg n=179 Participants
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52	-0.15415 Correlation coefficient	0.10486 Correlation coefficient	-0.06121 Correlation coefficient

Adverse Events

Rosuvastatin 10 mg

Serious events: 10 serious events

Other events: 15 other events

Deaths: 0 deaths

Rosuvastatin 40 mg

Serious events: 6 serious events

Other events: 16 other events

Deaths: 0 deaths

Atorvastatin 80 mg

Serious events: 5 serious events

Other events: 17 other events

Deaths: 0 deaths

Serious adverse events

Measure	Rosuvastatin 10 mg n=69 participants at risk	Rosuvastatin 40 mg n=87 participants at risk	Atorvastatin 80 mg n=80 participants at risk
Cardiac disorders Cardiac Failure	1.4% 1/69	0.00% 0/87	0.00% 0/80
Cardiac disorders Cardiac Failure Congestive	1.4% 1/69	0.00% 0/87	0.00% 0/80
Gastrointestinal disorders Enterocolitis	1.4% 1/69	0.00% 0/87	0.00% 0/80
Gastrointestinal disorders Dyspepsia	0.00% 0/69	0.00% 0/87	1.2% 1/80
Gastrointestinal disorders Gastritis	0.00% 0/69	0.00% 0/87	1.2% 1/80
Gastrointestinal disorders Gastrointestinal Haemorrhage	0.00% 0/69	1.1% 1/87	0.00% 0/80
General disorders Oedema Peripheral	0.00% 0/69	1.1% 1/87	0.00% 0/80
Infections and infestations Bronchitis	2.9% 2/69	0.00% 0/87	1.2% 1/80
Injury, poisoning and procedural complications Lumbar Vertebral Fracture	1.4% 1/69	0.00% 0/87	0.00% 0/80
Injury, poisoning and procedural complications Humerus Fracture	0.00% 0/69	1.1% 1/87	0.00% 0/80
Injury, poisoning and procedural complications Meniscus Lesion	0.00% 0/69	1.1% 1/87	0.00% 0/80
Metabolism and nutrition disorders Fluid Retention	1.4% 1/69	0.00% 0/87	0.00% 0/80
Musculoskeletal and connective tissue disorders Intervertebral Disc Protrusion	1.4% 1/69	0.00% 0/87	0.00% 0/80
Musculoskeletal and connective tissue disorders Musculoskeletal Chest Pain	0.00% 0/69	0.00% 0/87	1.2% 1/80
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Transitional Cell Carcinoma	1.4% 1/69	0.00% 0/87	0.00% 0/80
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast Cancer	0.00% 0/69	0.00% 0/87	1.2% 1/80
Nervous system disorders Hypertensive Encephalopathy	1.4% 1/69	0.00% 0/87	0.00% 0/80
Nervous system disorders Intracranial Aneurysm	0.00% 0/69	1.1% 1/87	0.00% 0/80
Renal and urinary disorders Renal Colic	1.4% 1/69	0.00% 0/87	0.00% 0/80
Renal and urinary disorders Nephrotic Syndrome	0.00% 0/69	1.1% 1/87	0.00% 0/80
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/69	0.00% 0/87	1.2% 1/80
Vascular disorders Hypertension	0.00% 0/69	1.1% 1/87	0.00% 0/80

Other adverse events

Measure	Rosuvastatin 10 mg n=69 participants at risk	Rosuvastatin 40 mg n=87 participants at risk	Atorvastatin 80 mg n=80 participants at risk
Gastrointestinal disorders Nausea	2.9% 2/69	6.9% 6/87	0.00% 0/80
Infections and infestations Nasopharyngitis	4.3% 3/69	6.9% 6/87	8.8% 7/80
Infections and infestations Bronchitis	5.8% 4/69	0.00% 0/87	0.00% 0/80
Infections and infestations Blood Creatine Phosphokinase Increased	4.3% 3/69	3.4% 3/87	5.0% 4/80
Musculoskeletal and connective tissue disorders Myalgia	5.8% 4/69	3.4% 3/87	6.2% 5/80
Nervous system disorders Dizziness	0.00% 0/69	1.1% 1/87	5.0% 4/80

Additional Information

Gerard Lynch

AstraZeneca

Email: aztrial_results_posting@astrazeneca.com

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place

Restriction type: LTE60